Compare MNY & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | CRVO |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 89.1M |
| IPO Year | N/A | N/A |
| Metric | MNY | CRVO |
|---|---|---|
| Price | $1.28 | $8.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $4.00 | ★ $21.50 |
| AVG Volume (30 Days) | ★ 88.7K | 86.6K |
| Earning Date | 12-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,182,746.00 | $6,159,786.00 |
| Revenue This Year | $11.26 | N/A |
| Revenue Next Year | $20.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $1.80 |
| 52 Week High | $2.40 | $16.94 |
| Indicator | MNY | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 53.05 |
| Support Level | $1.28 | $7.80 |
| Resistance Level | $1.60 | $10.00 |
| Average True Range (ATR) | 0.11 | 0.75 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 13.51 | 47.39 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.